DCP2 (Decapping MRNA 2)

We further explored the effects of the genes on cellular function and prognosis. In conclusion, this study provided a new perspective for the development mechanism of ovarian cancer.

These findings suggest that DCP2 may be involved in HCC progression by influencing mRNA degradation, cancer-related signaling, and the immune microenvironment. Although DCP2 shows potential as a diagnostic and prognostic biomarker, as well as a therapeutic target, further functional studies-such as gene knockdown and overexpression experiments-are needed to confirm its mechanistic role in the development of hepatocellular carcinoma (HCC).

Additionally, we observed that RCC with a high circKCNK2 expression could benefit from an anti-IL-11 strategy rather than a denosumab-based therapeutic regimen...Our findings suggest that circKCNK2 could have a critical role in linking P-bodies to IL-11/STAT-3 signaling. Developing a secure and effective gene delivery system targeted at circKCNK2 is promising for RCC therapy.

Half-maximal inhibitory concentrations (IC50) values of 47 drugs like paclitaxel differed between two risk groups...The RT-qPCR demonstrated that the expression of LSM2, LSM4, PUS7, SNRPC, and TUT1 were upregulated in OC, while DCP2, WTAP, and ZC3H13 were downregulated. We constructed an RNA modifications-related prognostic signature that can effectively predict clinical outcomes and therapeutic responses in patients with OC.

These results highlight the importance of ZFP36 activation in response to metformin treatment involving mTORC1 inhibition.